Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effective combinations of anti-cancer and targeted drugs for pancreatic cancer treatment
Arata Nishimoto
World Journal of Gastroenterology (2022) Vol. 28, Iss. 28, pp. 3637-3643
Open Access | Times Cited: 12

Showing 12 citing articles:

Gemcitabine effects on tumor microenvironment of pancreatic ductal adenocarcinoma: Special focus on resistance mechanisms and metronomic therapies
Jay Z. Natu, Ganji Purnachandra Nagaraju
Cancer Letters (2023) Vol. 573, pp. 216382-216382
Open Access | Times Cited: 30
Chemical Space of Fluorinated Nucleosides/Nucleotides in Biomedical Research and Anticancer Drug Discovery
Yugandhar Kothapalli, Tucker A. Lesperance, Ransom A. Jones, et al.
Chemistry (2025) Vol. 7, Iss. 1, pp. 7-7
Open Access
Identification of a chemoresistance-related prognostic gene signature by comprehensive analysis and experimental validation in pancreatic cancer
Junliang Chen, Zhihao Liu, Z. Wu, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 7
Discussion on gemcitabine combined with targeted drugs in the treatment of pancreatic cancer
Jun-Hao Huang, Wei Guo, Zhe Liu
World Journal of Gastroenterology (2023) Vol. 29, Iss. 3, pp. 579-581
Open Access | Times Cited: 6
Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin–Toxin Fusion in a Pancreatic Cancer Xenograft Model
Tianqi Xu, Alexey Schulga, Е. В. Коновалова, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2838-2838
Open Access | Times Cited: 5
An Efficient Fabrication Approach for Multi-Cancer Responsive Chemoimmuno Co-Delivery Nanoparticles
Jianxi Huang, Yu-Ting Chien, Qingxin Mu, et al.
Pharmaceutics (2024) Vol. 16, Iss. 10, pp. 1246-1246
Open Access | Times Cited: 1
Hawthorn with “homology of medicine and food”: a review of anticancer effects and mechanisms
Ziying Zhou, Yi Nan, Xiangyang Li, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Comparison of three exercise interventions with and without gemcitabine treatment on pancreatic tumor growth in mice: No impact on tumor infiltrating lymphocytes
Priti Gupta, Charles F. Hodgman, Claudia Alvarez‐Florez, et al.
Frontiers in Physiology (2022) Vol. 13
Open Access | Times Cited: 5
HANSynergy: Heterogeneous Graph Attention Network for Drug Synergy Prediction
Ning Cheng, Li Wang, Yiping Liu, et al.
Journal of Chemical Information and Modeling (2024) Vol. 64, Iss. 10, pp. 4334-4347
Closed Access
Establishment of a prognostic model for pancreatic cancer based on vesicle-mediated transport protein-related genes
Yanfang Cao, Renwei Xing, Fan Yang, et al.
Computer Methods in Biomechanics & Biomedical Engineering (2024), pp. 1-11
Closed Access
Prediction of synergistic gemcitabine-based combination treatment through a novel tumor stemness biomarker NANOG in pancreatic cancer
Jiongjia Cheng, Ting Zhu, Shaoxian Liu, et al.
RSC Medicinal Chemistry (2024)
Closed Access
Targeted Delivery of siRNA-Gemcitabine Oligonucleotide Chimeras for High-Efficacy Synergistic Treatment of Pancreatic Cancer
Ri Huang, Hong Du, Liang Cheng, et al.
Chemistry of Materials (2024)
Closed Access
Page 1

Scroll to top